Katianne Wanderley Rocha

Katianne Wanderley Rocha

Auto-generated profile, based on publicly available information

Katianne Wanderley Rocha

Centro Universitário Cesmac, Maceió, Alagoas, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Brazilian Journal of Otorhinolaryngology
Verified
Journal Article
Open access
KCKlinger V.T. da Costa
Klinger V.T. da Costa
ACAline Tenório Lins Carnaúba
Aline Tenório Lins Carnaúba
KRKatianne Wanderley Rocha
Katianne Wanderley Rocha
KAKelly Cristina Lira de Andrade
Kelly Cristina Lira de Andrade
SFSonia M.S. Ferreira
Sonia M.S. Ferreira
PMPedro de L. Menezes
Pedro de L. Menezes
The SARS-CoV-2 virus causes COVID-19, and it is responsible for the largest pandemic since the 1918 H1N1 influenza outbreak. The classic symptoms of the disease have been well defined by the World Health Organization; however, olfactory/gustatory disorders have been reported in some studies, but there are still several missing points in the understanding and in the consensus about the clinical management of these cases. To identify evidence in the scientific literature about olfactory/gustatory disorders, their clinical presentation, prevalence and possible specific treatments associated with COVID-19. A systematic review of articles published up to April 25, 2020 was performed in Medline, Cochrane Clinical Trials, ScienceDirect, Lilacs, Scopus and Google Schoolar, OpenGrey.eu, DissOnline, The New York Academy of Medicine and Reasearch Gate. (1) Studies on patients with COVID-19; (2) Records of COVID-19 signs/symptoms, and olfactory/gustatory functions. (1) Studies on non-human coronavirus; (2) Review articles; (3) Experimental studies (in animals or in vitro); (4) Olfactory/gustatory disorders initiated prior to SARS-CoV-2 infection. The risk assessment of bias of the selected studies was performed using the Newcastle-Ottawa scale. Six articles from the 1788 records met the inclusion criteria and were analyzed. A total of 1457 patients of different ethnicities were assessed; of them, 885 (60.7%) and 822 (56.4%) had smell and taste disorders, respectively, with women being most often affected. There were olfactory/gustatory disorders even without nasal obstruction/rhinorrhea and beginning even before the signs/symptoms of COVID-19; the recovery of smell/taste, when it occurs, usually happened in the first two weeks after COVID-19 resolution. There is evidence that olfactory/gustatory disorders are strong predictors of infection by SARS-CoV-2, and it is possible to recommend patient isolation, as early as of the medical consultation, preventing the spread of the virus. No scientific evidence has been identified for effective treatments for any of the disorders. Olfactory/gustatory disorders may occur at varying intensities and prior to the general symptoms of COVID-19 and should be considered as part of the clinical features of COVID-19, even in mild cases. There is still no scientific evidence of specific treatments for such disorders in COVID-19 disease.

30 June 2020 in Research Square
Verified
Preprint
Open access
PDF file
KCKlinger Vagner Teixeira da Costa
Klinger Vagner Teixeira da Costa
ACAline Tenório Lins Carnaúba
Aline Tenório Lins Carnaúba
KRKatianne Wanderley Rocha
Katianne Wanderley Rocha
KAKelly Cristina Lyra de Andrade
Kelly Cristina Lyra de Andrade
PMPedro de L. Menezes
Pedro de L. Menezes
ObjectiveTo conduct a systematic review with meta-analysis on the treatments for post-viral non-conductive olfactory disorder (NCSD) to be proposed for olfactory disorder in COVID-19.Study designSystematic review and meta-analysis with searches between June 10th and 13th, 2020 in the databases: Medline via PubMed, Cochrane Clinical Trials, ScienceDirect, Lilacs, Scopus, Google Schoolar and Web of Science and gray literature. Inclusion criteria: (1) clinical trials with NCSD; (2) olfactory assessment before and after the intervention using a validated method; exclusion criteria: (1) NCSD from neurological causes; (2) studies unrelated to NCSD treatment; (3) duplicate publications. The quality of the studies was assessed by two independent researchers according to the Cochrane Collaboration recommendations.ResultsA total of thirteen clinical trials met the criteria: nine on drug treatments and four on olfactory training with four odors. In drug treatments, caroverine, vitamin A, insulin, pentoxifylline, alpha-lipoic acid and sodium citrate were evaluated. The meta-analysis (336 patients) identified, through the random effect analysis, a statistically significant improvement between the TDI score before and after the olfactory training was observed (SMD = 5.18; 95% confidence interval (CI) [4.12, 6.23], p<0.00001).ConclusionSodium citrate and olfactory training are therapeutic approaches to recover olfactory function in post-viral NCSD and can be considered considered for NCSD due to COVID-19; however, further clinical trials are needed to confirm the results evaluated and establish treatment protocols.

1 November 2020 in Brazilian Journal of Otorhinolaryngology (Versão em Português)
Verified
Journal Article
Closed access
KCKlinger V.T. da Costa
Klinger V.T. da Costa
ACAline Tenório Lins Carnaúba
Aline Tenório Lins Carnaúba
KRKatianne Wanderley Rocha
Katianne Wanderley Rocha
KAKelly Cristina Lira de Andrade
Kelly Cristina Lira de Andrade
SFSonia M.S. Ferreira
Sonia M.S. Ferreira
PMPedro de L. Menezes
Pedro de L. Menezes